Baidu
map

Lancet Oncology:老年患早期乳腺癌术后建议辅助放疗

2015-01-28 MedSci MedSci原创

对于大多数老年女性早期乳腺癌患者来说,在保留乳房手术后的标准治疗方法是辅助全乳腺放疗以及辅助内分泌治疗。而来自英国爱丁堡大学肿瘤研究中心的Kunkler教授带领的研究小组,进行了一项3期随机对照临床试验,试图验证在在治疗5年局部复发风险较低的老年女性时,如果去除掉全乳腺放疗,是否能够产生良好的局部控制效果。本研究结果在线发表于2015年1月28日的the Lancet Oncology杂志上。

对于大多数老年女性早期乳腺癌患者来说,在保留乳房手术后的标准治疗方法是辅助全乳腺放疗以及辅助内分泌治疗。而来自英国爱丁堡大学肿瘤研究中心的Kunkler教授带领的研究小组,进行了一项3期随机对照临床试验,试图验证在在治疗5年局部复发风险较低的老年女性时,如果去除掉全乳腺放疗,是否能够产生良好的局部控制效果。本研究结果在线发表于2015年1月28日的the Lancet Oncology杂志上。

从2003年4月16日至2009年12月22日,该研究在4个国家的76个机构共招募了1326位65周岁以上的女性,经评估(例如:激素、受体阳性、腋下淋巴结阴性、T1-T2期且瘤体最长直径≤3cm、边缘清晰、肿瘤组织学或淋巴血管侵袭单项为3期,等)为低危早期乳腺癌。所有受试者此前接受过乳房保留手术,正接受辅助内分泌治疗。将符合条件的受试者通过计算机生成的置换区组随机化随机分为放疗组和无放疗组,通过各中心进行分层,区组长度为4。放疗组接受全乳腺放疗(40-50 Gy,分15-20次进行)。主要评估指标为同侧乳腺肿瘤复发。随访持续至最后一位受试患者结束治疗后10年止。通过意向治疗进行分析。

结果显示,共有658位女性在乳房保留手术后接受了辅助内分泌治疗以及全乳放疗,668位女性不接受放疗。在5年的中位随访期后(IQR 3•84–6•05),放疗组同侧乳腺肿瘤复发率为1.3 %(95% CI 0•2–2•3; n=5);无放疗组为4.1 %(2•4–5•7; n=26)。两组相比,放疗的乳腺肿瘤复发单因素风险比为5.19(95% CI 1•99–13•52; p=0•0007)。两组间局部复发、远端转移、侧乳腺癌或新发乳腺癌等无差异。两组的5年整体生存率为93.9 %(95% CI 91•8–96•0, p=0.34)。共89位受试者死亡,其中放疗组40人,无放疗组49人。放疗组中4人、无放疗组中8人死于乳腺癌。

通过随机化试验5年后的结果,研究人员得出结论:65岁以上的女性如果患有早期乳腺癌,在保留乳房手术后进行全乳放疗以及辅助内分泌疗法可以使肿瘤的局部控制能力明显上升。但是,同侧乳腺肿瘤的5年复发率很低,因此,对部分患者来说可以考虑术后不使用放疗。

本临床试验注册号为:ISRCTN95889329

原始出处

lan H Kunkler,Linda J Williams,Wilma J L Jack.et.al.Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.The Lancet Oncology.2014

本文是MedSci原创,欢迎转载,转载请注明出处,非常感谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674349, encodeId=662916e43491a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu May 07 22:24:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864596, encodeId=464d1864596f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 12 22:24:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827987, encodeId=1bdd182e9872a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Dec 20 13:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568304, encodeId=807e156830415, content=<a href='/topic/show?id=f5d69368591' target=_blank style='color:#2F92EE;'>#辅助放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93685, encryptionId=f5d69368591, topicName=辅助放疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=135c15357385, createdName=xuyu, createdTime=Fri Jan 30 08:24:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14798, encodeId=a25d14e9804, content=值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.213.53.**, createdTime=Wed Jan 28 23:30:00 CST 2015, time=2015-01-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674349, encodeId=662916e43491a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu May 07 22:24:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864596, encodeId=464d1864596f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 12 22:24:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827987, encodeId=1bdd182e9872a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Dec 20 13:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568304, encodeId=807e156830415, content=<a href='/topic/show?id=f5d69368591' target=_blank style='color:#2F92EE;'>#辅助放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93685, encryptionId=f5d69368591, topicName=辅助放疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=135c15357385, createdName=xuyu, createdTime=Fri Jan 30 08:24:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14798, encodeId=a25d14e9804, content=值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.213.53.**, createdTime=Wed Jan 28 23:30:00 CST 2015, time=2015-01-28, status=1, ipAttribution=)]
    2015-04-12 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674349, encodeId=662916e43491a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu May 07 22:24:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864596, encodeId=464d1864596f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 12 22:24:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827987, encodeId=1bdd182e9872a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Dec 20 13:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568304, encodeId=807e156830415, content=<a href='/topic/show?id=f5d69368591' target=_blank style='color:#2F92EE;'>#辅助放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93685, encryptionId=f5d69368591, topicName=辅助放疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=135c15357385, createdName=xuyu, createdTime=Fri Jan 30 08:24:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14798, encodeId=a25d14e9804, content=值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.213.53.**, createdTime=Wed Jan 28 23:30:00 CST 2015, time=2015-01-28, status=1, ipAttribution=)]
    2015-12-20 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674349, encodeId=662916e43491a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu May 07 22:24:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864596, encodeId=464d1864596f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 12 22:24:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827987, encodeId=1bdd182e9872a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Dec 20 13:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568304, encodeId=807e156830415, content=<a href='/topic/show?id=f5d69368591' target=_blank style='color:#2F92EE;'>#辅助放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93685, encryptionId=f5d69368591, topicName=辅助放疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=135c15357385, createdName=xuyu, createdTime=Fri Jan 30 08:24:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14798, encodeId=a25d14e9804, content=值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.213.53.**, createdTime=Wed Jan 28 23:30:00 CST 2015, time=2015-01-28, status=1, ipAttribution=)]
    2015-01-30 xuyu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1674349, encodeId=662916e43491a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu May 07 22:24:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864596, encodeId=464d1864596f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 12 22:24:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827987, encodeId=1bdd182e9872a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Dec 20 13:24:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568304, encodeId=807e156830415, content=<a href='/topic/show?id=f5d69368591' target=_blank style='color:#2F92EE;'>#辅助放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93685, encryptionId=f5d69368591, topicName=辅助放疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=135c15357385, createdName=xuyu, createdTime=Fri Jan 30 08:24:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14798, encodeId=a25d14e9804, content=值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.213.53.**, createdTime=Wed Jan 28 23:30:00 CST 2015, time=2015-01-28, status=1, ipAttribution=)]
    2015-01-28 180.213.53.**

    值得借鉴

    0

相关资讯

NEJM:依西美坦或为年轻乳腺癌患者的新选择

对于已接受卵巢功能抑制治疗的激素受体阳性的早期乳腺癌">乳腺癌患者来言,依西美坦辅助化疗较他莫昔芬比或更能提高预后。 激素受体阳性的早期乳腺癌绝经前女性都会接受至少5-10年他莫昔芬的治疗。但是卵巢功能抑制(OFS)治疗联合他莫昔芬或芳香酶抑制剂(AI)治疗,二者的复发率、生存率孰优孰劣尚不得知。 研究者们开展了2项随机的Ⅲ期临床试验(TEXT试验 和 SOFT试验),对比卵巢OFS联合

日本拟用患者自体干细胞再造乳房

日媒称,位于神奈川县镰仓市的湘南镰仓综合医院21日宣布,该院近期将实施患者自体干细胞乳房再造治疗,以帮助那些因乳腺癌">乳腺癌手术失去或导致乳房变形的患者实现乳房再造。此种治疗手段的安全性和有效性已通过临床试验得到确认。 据日本《东京新闻》1月22日报道,预计治疗实施计划将在2月得到有关部门批准,一旦获准将迅速开始接受患者申请。据院方介绍,此次通过“脂肪干细胞移植”进行的乳房再造在日本尚属

Mol Pharmacol::乳腺癌,胰腺癌治疗新可能

近日,美国佛罗里达州的克里普斯研究所(TSRI)的研究人员发现了一种新型合成的化合物,名为SR1848。这种化合物能通过抑制一种肿瘤相关的重要蛋白-“LRH-1”的合成和活性,从而有效的减缓胰腺癌和乳腺癌的发展。这篇研究讲发表在2月刊的Molecular Pharmacology杂志上。 LRH1被认为是乳腺癌的危险因素是因为它参与激素的合成和胆固醇的代谢。最近,LRH-1也已显示能促进肠和胰腺

适合中国女性的早期乳腺癌带蒂皮瓣术

乳腺癌">乳腺癌是女性最为常见的恶性肿瘤之一,国内乳腺癌患者平均年龄为48.7岁,完全的乳房切除给女性遗留下的疤痕严重影响患者的身心健康及社会和家庭生活。乳房重建被证明可以改善患者的生活质量。肿瘤切除后即刻进行乳房重建具有较高的可行性,这样不仅可以解救乳房轮廓,并且具有较好的成本效益。 目前有以下几种手术方式:使用腹横直肌皮肌(transverse rectus abdominis myo

美国国家癌症研究院:乳腺癌风险因素与预防措施面面观

除了女性性别,年龄增长是最大的乳腺癌危险因素。增加内源性雌激素水平的生殖因素,如初潮早、绝经晚,绝经后使用结合雌孕激素增加风险。未育和饮酒也与风险增加有关。 乳腺癌家族史或个人病史有浸润性乳腺癌、导管原位癌或小叶原位癌,或乳房活检史显示良性增生性疾病增加乳腺癌风险。 乳房密度增加也使乳腺癌的风险增加。它通常是一个遗传的特质,但也经常见于无育、晚育、绝经后使用激素治疗和饮酒的女性。

Nature Communicaiton:通过HIF-1抑制乳腺癌转移新策略

近日,国际期刊Nature Communication在线发表了日本科学家的一项最新研究成果,发现泛素C端水解酶L1(UCHL1)能够作为HIF-1a的去泛素化酶促进肿瘤转移,表明或许可以利用UCHL1作为肿瘤转移诊断标记和癌症治疗靶点。   HIF-1在肿瘤中转移过程中发挥重要作用,但能够激活HIF-1并进一步促进肿瘤转移的基因仍没有得到鉴定。研究人员发现UCHL1能够减弱VH

Baidu
map
Baidu
map
Baidu
map